140 related articles for article (PubMed ID: 24564991)
1. [Chronic myeloid leukemia treatment and human immunodeficiency virus infection].
Campillo-Recio D; Perez-Rodriguez L; Yebra E; Cervero-Jimenez M
Rev Clin Esp (Barc); 2014 May; 214(4):231-2. PubMed ID: 24564991
[No Abstract] [Full Text] [Related]
2. A patient of chronic myelogenous leukemia developing painful rash on feet.
Kumar P; Das NK; Sil A; Chakrabarti P
J Postgrad Med; 2012; 58(4):331-4. PubMed ID: 23298941
[No Abstract] [Full Text] [Related]
3. [Chronic myelogenous leukemia: management of treatment-related adverse events].
Takahashi N
Rinsho Ketsueki; 2012 Oct; 53(10):1581-8. PubMed ID: 23037730
[No Abstract] [Full Text] [Related]
4. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
[TBL] [Abstract][Full Text] [Related]
5. [Fulminating hepatitis for imatinib in a patient with chronic myeloid leukaemia].
Martínez Pascual C; Valdés Mas M; de la Peña Moral JM; Miras López M
Med Clin (Barc); 2011 Sep; 137(7):329-30. PubMed ID: 21074222
[No Abstract] [Full Text] [Related]
6. [Chronic myeloid Leukemia - clinical practice according to the JSH guideline for hematological malignancies].
Yahagi Y
Gan To Kagaku Ryoho; 2014 May; 41(5):567-71. PubMed ID: 24956628
[No Abstract] [Full Text] [Related]
7. Effectiveness of imatinib therapy for sickle cell anemia and chronic myeloid leukemia.
Murphy M; Close J; Lottenberg R; Rajasekhar A
Am J Med Sci; 2014 Mar; 347(3):254-5. PubMed ID: 24553361
[No Abstract] [Full Text] [Related]
8. Periungual pyogenic granuloma following imatinib therapy in a patient with chronic myelogenous leukemia.
Dika E; Barisani A; Vaccari S; Fanti PA; Ismaili A; Patrizi A
J Drugs Dermatol; 2013 May; 12(5):512-3. PubMed ID: 23652942
[No Abstract] [Full Text] [Related]
9. Multiple eruptive dermatofibromas related to imatinib treatment.
Llamas-Velasco M; Fraga J; Solano-López GE; Steegmann JL; García Diez A; Requena L
J Eur Acad Dermatol Venereol; 2014 Jul; 28(7):979-81. PubMed ID: 24321053
[No Abstract] [Full Text] [Related]
10. Peripheral neuropathy as an adverse effect of imatinib therapy.
Chakupurakal G; Etti RJ; Murray JA
J Clin Pathol; 2011 May; 64(5):456. PubMed ID: 21278395
[No Abstract] [Full Text] [Related]
11. Oral melanosis after tyrosine kinase inhibition with Imatinib for chronic myelogenous leukemia: report of a case and review of the literature.
Wong M; Sade S; Gilbert M; Klieb HB
Dermatol Online J; 2011 May; 17(5):4. PubMed ID: 21635826
[TBL] [Abstract][Full Text] [Related]
12. Sequential transient novel chromosomal translocations in a patient with chronic myelogenous leukemia in complete cytogenetic remission after therapy with imatinib mesylate.
Papaioannou G; Athanasiadou A; Voutiadou G; Gaitatzi M; Batsis I; Touloumenidou T; Anagnostopoulos A
Cancer Genet; 2011 Dec; 204(12):692-3. PubMed ID: 22285023
[No Abstract] [Full Text] [Related]
13. Vocal fold hemorrhage in a CML patient after Glivec treatment.
Shim HS; Woo SH
Acta Oncol; 2013 May; 52(4):866-8. PubMed ID: 23153030
[No Abstract] [Full Text] [Related]
14. Long-term molecular efficacy and safety of imatinib in a patient with chronic myeloid leukaemia after renal transplantation.
Thierry A; Dreyfus B; Bridoux F; Abou Ayache R; Milin S; Guilhot F; Touchard G
Nephrol Dial Transplant; 2007 Jun; 22(6):1791-2. PubMed ID: 17308316
[No Abstract] [Full Text] [Related]
15. A limited but necessary indication of stem cell transplantation for chronic myelogeneous leukemia in the era of tyrosine kinase inhibitors.
Imataki O
Transplantation; 2014 Jan; 97(1):e4-5. PubMed ID: 24374768
[No Abstract] [Full Text] [Related]
16. TK inhibitor treatment disrupts growth hormone axis: clinical observations in children with CML and experimental data from a juvenile animal model.
Ulmer A; Tabea Tauer J; Glauche I; Jung R; Suttorp M
Klin Padiatr; 2013 May; 225(3):120-6. PubMed ID: 23716272
[TBL] [Abstract][Full Text] [Related]
17. Massive bone marrow necrosis in a patient with chronic myelocytic leukemia following imatinib mesylate therapy.
Tamura T; Tasaka T; Fujimoto M; Matsuhashi Y; Fukumot T; Mano S; Kuwajima M; Nagai M
Haematologica; 2004 Sep; 89(9):ECR32. PubMed ID: 15377484
[No Abstract] [Full Text] [Related]
18. Imatinib-lnduced agranulocytosis in a patient with chronic myelogenous leukemia in remission.
Khouri S; Kotliroff A; Lishner M; Amital H
Isr Med Assoc J; 2008 Apr; 10(4):320-1. PubMed ID: 18548994
[No Abstract] [Full Text] [Related]
19. [Survival following liver transplant due to imatinib-induced acute liver failure: a case study].
García-Valdés M; Miras López M; Garrido Corro B; De La Rubia Nieto A
Farm Hosp; 2012; 36(1):50-1. PubMed ID: 21514865
[No Abstract] [Full Text] [Related]
20. [Standard therapy for chronic myelogenous leukemia].
Kimura S
Rinsho Ketsueki; 2012 Oct; 53(10):1571-80. PubMed ID: 23037729
[No Abstract] [Full Text] [Related]
[Next] [New Search]
